Search results for "cancer research"

showing 10 items of 5684 documents

ShRNA-mediated knock-down of CXCL8 inhibits tumor growth in colorectal liver metastasis.

2018

CXCL8 belongs to proinflammatory chemokines that are predominantly involved in neutrophil chemotaxis and degranulation. Several studies have suggested that secretion of CXCL8 from cancer cells have a profound effect on tumor microenvironment. In this study, in continuation to our previous work of understanding the global picture of invasion related genes in colorectal liver metastases, we clearly show an up-regulation of CXCL8 expression in the tumor cells at the invasion front as compared to the tumor cells in the inner parts of the tumor. Furthermore, ShRNA mediated down-regulation of CXCL8 resulted in inhibition of cell proliferation, viability and invasion in vitro and a near complete g…

musculoskeletal diseases0301 basic medicineAngiogenesisCell SurvivalBiophysicsDown-RegulationApoptosisBiologyBiochemistryProinflammatory cytokineMetastasis03 medical and health sciencesMice0302 clinical medicineCell Line TumormedicineAnimalsHumansNeoplasm InvasivenessAmino Acid SequenceRNA MessengerRNA Small InterferingMolecular BiologyProtein kinase BConserved SequenceCell ProliferationTumor microenvironmentInterleukin-8Liver NeoplasmsCell Biologymedicine.diseaseXenograft Model Antitumor AssaysUp-RegulationGene Expression Regulation NeoplasticVascular endothelial growth factor A030104 developmental biologyTumor progression030220 oncology & carcinogenesisGene Knockdown TechniquesCancer cellCancer researchColorectal NeoplasmsBiochemical and biophysical research communications
researchProduct

Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis

2019

Abstract Despite the advances in the treatment of rheumatoid arthritis (RA) achieved in the last few years, several patients are diagnosed late, do not respond to or have to stop therapy because of inefficacy and/or toxicity, leaving still a huge unmet need. Tissue-specific strategies have the potential to address some of these issues. The aim of the study is the development of a safe nanotechnology approach for tissue-specific delivery of drugs and diagnostic probes. CD34 + endothelial precursors were addressed in inflamed synovium using targeted biodegradable nanoparticles (tBNPs). These nanostructures were made of poly-lactic acid, poly-caprolactone, and PEG and then coated with a synovi…

musculoskeletal diseases0301 basic medicineBiodistributionCD34; +; cells; Neoangiogenesis; Rheumatoid arthritis; Targeted nanoparticles; Targeted therapymedicine.medical_treatmentTargeted nanoparticlesImmunologyArthritisInflammation+Targeted therapyTargeted therapy03 medical and health sciences0302 clinical medicinemedicineImmunology and AllergyProgenitor cellRheumatoid arthritisRheumatoid arthritiTargeted nanoparticleNeoangiogenesis030203 arthritis & rheumatologybusiness.industrycellmedicine.diseaseNeoangiogenesi030104 developmental biologyRheumatoid arthritisToxicityCancer researchcellsMethotrexateCD34medicine.symptombusinessmedicine.drug
researchProduct

Progestogens and risk of breast cancer: a link between bone and breast?

2015

This article reviews the data supporting the role of receptor activator of the nuclear factor kappa (RANK) and its ligand, RANKL, in progestogen-induced breast cancer. Both experimental and clinical studies have been included. The expression of both RANK and RANKL has been described in epithelial cells of both mice and humans. Experiments of gain and loss of function in mice have shown that RANK/RANKL mediate alveologenesis during pregnancy or the estrous cycle. Moreover, the participation of the RANK/RANKL has been detected in models of breast carcinogenesis associated with progestogens-like medroxyprogesterone acetate. Recent clinical studies have found that the expression of RANK is asso…

musculoskeletal diseases0301 basic medicineEndocrinology Diabetes and MetabolismOsteoclastsBone NeoplasmsBreast NeoplasmsMice03 medical and health sciences0302 clinical medicineEndocrinologyBreast cancerRisk FactorsmedicineAnimalsHumansMedroxyprogesterone acetateBreastReceptorProgesteroneLoss functionEstrous cyclePregnancyReceptor Activator of Nuclear Factor-kappa BbiologyActivator (genetics)business.industryRANK LigandObstetrics and Gynecologymedicine.disease030104 developmental biologyRANKL030220 oncology & carcinogenesisImmunologybiology.proteinCancer researchFemaleProgestinsbusinessmedicine.drugGynecological Endocrinology
researchProduct

Influence of the anti-inflammatory cytokine interleukin-4 on human joint capsule myofibroblasts

2016

Post-traumatic joint contracture was reported to be associated with elevated numbers of contractile myofibroblasts (MFs) in the healing capsule. During the physiological healing process, the number of MFs declines; however, in fibroconnective disorders, MFs persist. The manifold interaction of the cytokines regulating the appearance and persistence of MFs in the pathogenesis of joint contracture remains to be elucidated. The objective of our current study was to analyze the impact of the anti-inflammatory cytokine interleukin (IL)-4 on functional behavior of MFs. Cells were isolated from human joint capsule specimens and challenged with three different concentrations of IL-4 with or without…

musculoskeletal diseases0301 basic medicinemedicine.medical_treatmentInterleukinBiology03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureCytokineJoint capsuleGene expressionImmunologyCancer researchmedicineOrthopedics and Sports MedicineJoint ContractureReceptorMyofibroblastInterleukin 4030215 immunologyJournal of Orthopaedic Research
researchProduct

Clonal heterogeneity of the growth and invasive response of a human breast carcinoma cell line to parathyroid hormone-related peptide fragments

1997

It has been previously reported that 8701-BC cells, derived from a primary carcinoma of the breast, constitutively express parathyroid hormone (PTH)-related peptide (PTHrP) and PTH/PTHrP receptor (PTH/PTHrP-R) genes, that N-terminal, mid-regional and C-terminal immunoreactive PTHrP can be found in cell conditioned medium and, furthermore, that exogenously added PTHrP (1-34), (67-86) and, to a minor extent, (107-139) are anti-mitogenic but promote Matrigel invasion by this cell line. It has also been reported that PTHrP gene expression is selectively switched on in those 8701-BC clonal lines endowed with a higher proliferation rate and invasive ability in vitro. Here we have first examined t…

musculoskeletal diseasesCancer Researchmedicine.medical_specialtyPopulationParathyroid hormoneBreast NeoplasmsBiologyInternal medicineGene expressionTumor Cells CulturedmedicineHumansNeoplasm Invasivenesseducationeducation.field_of_studyParathyroid hormone-related proteinCell growthParathyroid hormone receptorParathyroid Hormone-Related ProteinProteinsGeneral Medicinemusculoskeletal systemMolecular biologyPeptide FragmentsNeoplasm ProteinsEndocrinologyParathyroid HormoneCell cultureFemaleClone (B-cell biology)Cell Divisionhormones hormone substitutes and hormone antagonistsCarcinogenesis
researchProduct

Compliance and arthralgias in clinical therapy (COMPACT): Assessment of the incidence of arthralgia, therapy costs, and compliance in the first year …

2012

e11040^ Background: Aromatase Inhibitors (AI) are well established as adjuvant endocrine treatment for postmenopausal women with HR+ early breast cancer (EBC). However, clinical trial data show higher frequently of arthralgia with AI than tamoxifen. As arthralgia may be greatly influencing compliance to adjuvant therapy, we designed a prospective trial to collect real world data on the effects of AI-associated arthralgia on patient compliance, patient outcomes and treatment costs of arthralgia. Methods: COMPACT is an open, prospective non-interventional study (NCT00857012) assessing the incidence of arthralgia, therapy costs, and compliance within the first year of adjuvant anastrozole (AN…

musculoskeletal diseasesCancer Researchmedicine.medical_specialtybiologybusiness.industrymedicine.medical_treatmentIncidence (epidemiology)Anastrozolebody regionsClinical trialCompliance (physiology)Clinical therapyOncologyInternal medicinemedicinebiology.proteinEndocrine systemAromataseskin and connective tissue diseasesbusinessAdjuvantmedicine.drugJournal of Clinical Oncology
researchProduct

Effect of patella resurfacing on functional outcome and revision rate in primary total knee arthroplasty (Review).

2021

Anterior knee pain, as well as patellofemoral disorders, after total knee arthroplasty are important reasons for revision in total knee arthroplasty. Current prosthesis designs include patellar components for patella replacement, and together with improved rational design of the prosthesis and advancement in knee alignment these appear to reduce the incidence of anterior knee pain following total knee replacement, even if the etiology of anterior knee pain remains unclear. However, new complications related to patella resurfacing emerge with this approach. At present, there are three strategies involving patella replacement in total knee arthroplasty: There are surgeons who always replace t…

musculoskeletal diseasesCancer Researchmedicine.medical_specialtybusiness.industryTotal knee arthroplastyGeneral MedicineReviewmusculoskeletal systemSurgeryImmunology and Microbiology (miscellaneous)medicineRevision ratePatellabusinesshuman activitiesExperimental and therapeutic medicine
researchProduct

Osteoprotegerin expression in liver is induced by IL-13 through TGF-β

2020

1.AbstractBackgroundsOsteoprotegerin (OPG) is a profibrotic mediator produced by myofibroblasts under influence of transforming growth factor β (TGFβ). Its expression in experimental models of liver fibrosis correlates well with disease severity and treatment responses. The regulation of OPG in liver tissue is largely unknown and we therefore set out to elucidate which growth factors/interleukins associated with fibrosis induce OPG and through which pathways.MethodsPrecision-cut liver slices of wild type and STAT6-deficient mice and 3T3 fibroblasts were used to investigate the effects of TGFβ, interleukin (IL) 13 (IL13), IL1β, and platelet-derived growth factor BB (PDGF-BB) on expression of…

musculoskeletal diseasesChemistryGrowth factormedicine.medical_treatmentmedicine.diseaseAP-1 transcription factorOsteoprotegerinDownregulation and upregulationFibrosisInterleukin 13medicineCancer researchGalunisertibTransforming growth factor
researchProduct

COX-2 expression in chondrosarcoma: A role for celecoxib treatment?

2010

Chondrosarcomas are resistant to conventional chemo- and radiotherapy. A subset of chondrosarcomas arises secondarily in the benign tumour syndromes enchondromatosis (EC) and multiple osteochondromas (MO), and prevention of tumour development would greatly improve prognosis. We therefore investigated the effect of selective COX-2 inhibition on chondrosarcoma growth. COX-2 expression was studied in central- and peripheral cartilaginous tumours. The effect of COX-2 inhibition was assessed in four high-grade chondrosarcoma cell lines using celecoxib and NS-398 treatment. COX-2 activity (prostaglandin E-2 (PGE(2)) ELISA) and cell viability were measured. The (prophylactic) effect of celecoxib o…

musculoskeletal diseasesMaleCancer ResearchPathologymedicine.medical_specialtyCell Survivalmedicine.medical_treatmentChondrosarcomaDrug Evaluation PreclinicalMice NudeAntineoplastic AgentsBone NeoplasmsMiceIn vivomedicineTumor Cells CulturedAnimalsHumansViability assaySulfonamidesCyclooxygenase 2 Inhibitorsbusiness.industryCartilagemedicine.diseaseXenograft Model Antitumor AssaysRadiation therapyDisease Models Animalmedicine.anatomical_structureOncologyBone tumours Chondrosarcoma COX-2 inhibition Therapy Xenograft familial adenomatous polyposis cell-line cyclooxygenase-2 inhibitor trial tumors establishment emphasis origin boneCell cultureCelecoxibCyclooxygenase 2CelecoxibPyrazolesChondrosarcomabusinessmedicine.drugProstaglandin E
researchProduct

Evaluation of the osteoclastogenic process associated with RANK / RANK-L / OPG in odontogenic myxomas

2018

Background Odontogenic myxoma (OM) is a benign intraosseous neoplasm that exhibits local aggressiveness and high recurrence rates. Osteoclastogenesis is an important phenomenon in the tumor growth of maxillary neoplasms. RANK (Receptor Activator of Nuclear Factor κappa B) is the signaling receptor of RANK-L (Receptor activator of nuclear factor kappa-Β ligand) that activates the osteoclasts. OPG (osteoprotegerin) is a decoy receptor for RANK-L that inhibits pro-osteoclastogenesis. The RANK / RANKL / OPG system participates in the regulation of osteolytic activity under normal conditions, and its alteration has been associated with greater bone destruction, and also with tumor growth. Object…

musculoskeletal diseasesMaleOdontogenic myxomaRANK-LRANKOdontogenic myxoma03 medical and health sciences0302 clinical medicineOsteoprotegerinOsteoclastogenesis.MedicineNeoplasmHumansMIXOMAReceptorGeneral DentistryLanguageOSTEOGENESISDental follicleOral Medicine and PathologybiologyActivator (genetics)business.industryResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDental follicleLIGANDO RANKOtorhinolaryngologyRANKL030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASCancer researchbiology.proteinImmunohistochemistryOPGSurgerybusinessMyxomaMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct